All articles tagged with #breast cancer drug
The FDA issued an untitled letter to Novartis, criticizing a TV commercial for the breast cancer drug Kisqali as containing "false or misleading" information. The ad, which featured a "Long Live" tagline and ran from 2022 to September 2023, was flagged for potentially giving metastatic breast cancer patients an exaggerated impression of the drug's effectiveness in treating their condition and symptoms.
A study from the Memorial Sloan Kettering Cancer Center has found that the breast cancer drug alpelisib can cause elevated blood sugar rates, or hyperglycemia, in some patients. Among 147 patients treated with alpelisib, the rate of hyperglycemia was 80.3%, with 40.2% experiencing serious hyperglycemia. The condition typically began 16 days after starting the medication, and patients with pre-existing diabetes or pre-diabetes were at a higher risk. While hyperglycemia is a known side effect, doctors believe it can be managed through monitoring and lifestyle changes. Alternative treatment options are available for patients who experience this side effect.
A recent study presented at the American Society of Clinical Oncology has found that the breast cancer drug talazoparib may be effective against a wide range of other cancers. The study evaluated the use of talazoparib in 28 cancer patients with different types of tumors, all of whom had a specific gene mutation. Despite being heavily pretreated and having exhausted other treatment options, the patients showed a 57% rate of disease control, with 36% experiencing tumor shrinkage. The findings suggest that talazoparib and other PARP inhibitors could be used to treat cancer patients with specific gene mutations, potentially expanding treatment options for a broader range of cancers.